AURKC
Overview
AURKC (aurora kinase C) is a serine/threonine kinase in the aurora kinase family, playing roles in chromosome segregation and cytokinesis. In oral squamous cell carcinoma (OSCC), AURKC was identified as altered (copy number gain) and grouped with AURKA as an Aurora kinase pair with clinical-trial-stage inhibitors available at the time of publication.
Alterations observed in the corpus
- Copy number alteration (gain) in OSCC; Aurora kinases AURKA and AURKC collectively altered in 14% (5/35) of OSCC tumors (hnsc_mdanderson_2013); drugs in clinical trials noted. PMID:23619168
Cancer types (linked)
- OCSC / HNSC: copy number gain in 14% of OSCC tumors as part of the 80% targetable-alteration landscape. PMID:23619168
Co-occurrence and mutual exclusivity
- Co-altered with AURKA in the 14% Aurora kinase-altered OSCC subgroup; both are within the broader mitogenic-pathway alteration landscape. PMID:23619168
Therapeutic relevance
- Aurora kinase inhibitors (targeting AURKA/B/C) were in clinical trials at the time of this study; AURKC copy gain in OSCC supports rationale for Aurora kinase inhibitor investigation in this disease. PMID:23619168
Open questions
- Specific frequency of AURKC versus AURKA alterations within the 14% combined figure is not separately reported; functional significance of AURKC copy gain in OSCC is not experimentally validated. PMID:23619168
Sources
This page was processed by crosslinker on 2026-05-09.